摘要
目的:比较2μm激光与等离子电切治疗良性前列腺增生(BPH)的疗效,系统评价2μm激光临床应用效果,为临床提供参考依据。方法:收集已发表的关于2μm激光和等离子电切治疗BPH的国内外文献,针对结果进行统计学综合分析(Meta)。终末指标采用SMD值及95%CI进行比较分析,统计学处理采用Revman5.0软件。结果:共7篇文献符合纳入标准,对2μm激光组的463例和等离子电切组的608例进行分析。Meta分析显示:1等离子电切组手术时间少于2μm激光组,差异有统计学意义(P<0.01);22μm激光组术中出血量小于等离子电切组,差异有统计学意义(P<0.01);32μm激光组术后留置尿管时间少于等离子电切组,差异有统计学意义(P<0.01);42μm激光组膀胱冲洗时间少于等离子电切组,差异有统计学意义(P<0.01);52μm激光组住院时间少于等离子电切组,差异有统计学意义(P<0.01)。结论:2μm激光具有出血少、创伤小、术后恢复快等优势,治疗BPH安全可靠。
Objective:To compare the efficacy of 2μm laser resection and plasmakinetic resection for BPH,and to evaluate clinical effects of 2μm laser so as to provide clinical reference.Method:We retrieved published comparative studies of 2μm laser resection and plasmakinetic resection for BPH,and pooled the data from eligible studies(Meta-analysis).Standardized mean difference and its 95% confidence interval(CI)were used as the measurement parameter of efficacy comparison.The statistical analyses were performed using Revman 5.0software.Result:Five trials included 463 patients treated with 2μm laser resection and 608 cases treated with plasmakinetic resection.Pooling data showed:1operative time of plasmakinetic procedure was less than 2μm laser resection(P 〈0.01);2intraoperative blood loss of 2μm laser group was less than plasmakinetic group,which the difference was statistically significant(P 〈0.01);3comparing postoperative indwelling catheter time between the two groups,2μm laser has a less time than the plasmakinetic group,which the difference was statistically significant(P〈0.01);4bladder irrigation time was significantly different between two groups,2μm laser group has a shorter time(P 〈0.01);5hospital stay of 2μm laser group was shorter than the plasmakinetic group,and the difference was statistically significant(P〈0.01).Conclusion:The treatment of 2μm laser is safe and reliable to BPH with less blood loss,fewer traumas,quicker recovery and other advantages.
出处
《临床泌尿外科杂志》
2014年第8期681-684,共4页
Journal of Clinical Urology
关键词
2ΜM激光
等离子电切
良性前列腺增生
疗效
2μm laser
plasmakinetic resection
benign prostatic hyperplasia
efficacy